NL-OMON44222招募中3 期
Efficacy of rituximab in comparison to continued corticosteroid treatment in idiopathic nephrotic syndrome unresponsive to 8 weeks of high dose prednisone. - Rituximab in SRNS
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Age >= 18 years
- •Persistent proteinuria >= 2 g/ 24 hours or a protein-to-creatinine ratio >= 2 g/10mmol (2 g/g) after 8 weeks of treatment with high dose prednisone 1 mg/kg/day (max 80 mg/day)
- •Idiopathic nephrotic syndrome caused by biopsy proven minimal change disease or focal segmental glomerulosclerosis
排除标准
- •Severe nephrotic syndrome with hypotension
- •Previous treatment with immunosuppressive medication other than prednisone
- •Treatment with prednisone > 10 weeks in last six months
- •Secondary form of FSGS or minimal change disease
- •Patients who test positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody
- •(anti-HBc).
- •Patients infected with HIV or suffering from other active infections
- •Patients inoculated with a live vaccine within 4 weeks prior to inclusion
- •Pregnancy, breast feeding, women with inadequate contraception
- •Malignancy
- •Kidney transplantation
- •Previous treatment with monoclonal antibodies
研究者
相似试验
进行中（未招募）
1 期
Comparison of rituximab with prolonged treatment with prednisone in patients with idiopathic nephrotic syndromeEUCTR2017-003366-27-NLRadboud University Nijmegen Medical Center40
进行中（未招募）
1 期
Comparison of two treatments rituximab in patients with autoimmune disease resistant to conventional treatmentsEUCTR2011-005856-32-ESFundación Progreso y Salud9
招募中
1 期
The effects of Rituximab and CyclosporineSteroid-resistant nephrotic syndrome.IRCT20240614062128N1Ghoum University of Medical Sciences76
进行中（未招募）
不适用
Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blockerTo investigate the efficacy of treatment with Rituximab (MabThera®) in patients with active RA whose current treatment with one or more TNF-blocker (Etanercept - Enbrel®, Infliximab – Remicade® or Adalimumab - Humira®) alone or in combination with MTX is insufficient measured by DAS28 activity index.EUCTR2006-004673-98-HURoche (Hungary) Ltd.20
进行中（未招募）
不适用
Efficacy and safety of rituximab in patients with rheumatoid arthritis - FIRSTMedDRA version: 8.1Level: PTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2006-001000-37-DERoche Pharma AG300